Maturation-induced conformational changes of HIV-1 capsid protein and identification of two high affinity sites for cyclophilins in the C-terminal domain by Endrich, M M et al.
University of Zurich





Maturation-induced conformational changes of HIV-1 capsid
protein and identification of two high affinity sites for
cyclophilins in the C-terminal domain
Endrich, M M; Gehrig, P; Gehring, H
Endrich, M M; Gehrig, P; Gehring, H. Maturation-induced conformational changes of HIV-1 capsid protein and




Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.unizh.ch
Originally published at:
J. Biol. Chem. 1999, 274(9):5326-32
Endrich, M M; Gehrig, P; Gehring, H. Maturation-induced conformational changes of HIV-1 capsid protein and




Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.unizh.ch
Originally published at:
J. Biol. Chem. 1999, 274(9):5326-32
Maturation-induced conformational changes of HIV-1 capsid
protein and identification of two high affinity sites for
cyclophilins in the C-terminal domain
Abstract
Viral incorporation of cyclophilin A (CyPA) during the assembly of human immunodeficiency virus
type-1 (HIV-1) is crucial for efficient viral replication. CyPA binds to the previously identified
Gly-Pro90 site of the capsid protein p24, but its role remained unclear. Here we report two new
interaction sites between cyclophilins and p24. Both are located in the C-terminal domain of p24 around
Gly-Pro157 and Gly-Pro224. Peptides corresponding to these regions showed higher affinities (Kd
approximately 0.3 microM) for both CyPA and cyclophilin B than the best peptide derived from the
Gly-Pro90 site ( approximately 8 microM) and thus revealed new sequence motifs flanking Gly-Pro that
are important for tight interaction of peptide ligands with cyclophilins. Between CyPA and an immature
(unprocessed) form of p24, a Kd of approximately 8 microM was measured, which corresponded with
the Kd of the best of the Gly-Pro90 peptides, indicating an association via this site. Processing of
immature p24 by the viral protease, yielding mature p24, elicited a conformational change in its
C-terminal domain that was signaled by the covalently attached fluorescence label acrylodan.
Consequently, CyPA and cyclophilin B bound with much higher affinities ( approximately 0.6 and 0.25
microM) to the new, i.e. maturation-generated sites. Since this domain is essential for p24
oligomerization and capsid cone formation, CyPA bound to the new sites might impair the regularity of
the capsid cone and thus facilitate in vivo core disassembly after host infection.
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Viral incorporation of cyclophilin A (CyPA) during the
assembly of human immunodeficiency virus type-1
(HIV-1) is crucial for efficient viral replication. CyPA
binds to the previously identified Gly-Pro90 site of the
capsid protein p24, but its role remained unclear. Here
we report two new interaction sites between cyclophil-
ins and p24. Both are located in the C-terminal domain
of p24 around Gly-Pro157 and Gly-Pro224. Peptides corre-
sponding to these regions showed higher affinities (Kd ;
0.3 mM) for both CyPA and cyclophilin B than the best
peptide derived from the Gly-Pro90 site (;8 mM) and thus
revealed new sequence motifs flanking Gly-Pro that are
important for tight interaction of peptide ligands with
cyclophilins. Between CyPA and an immature (unproc-
essed) form of p24, a Kd of ;8 mM was measured, which
corresponded with the Kd of the best of the Gly-Pro
90
peptides, indicating an association via this site. Process-
ing of immature p24 by the viral protease, yielding ma-
ture p24, elicited a conformational change in its C-ter-
minal domain that was signaled by the covalently
attached fluorescence label acrylodan. Consequently,
CyPA and cyclophilin B bound with much higher affin-
ities (;0.6 and 0.25 mM) to the new, i.e. maturation-gen-
erated sites. Since this domain is essential for p24 oli-
gomerization and capsid cone formation, CyPA bound to
the new sites might impair the regularity of the capsid
cone and thus facilitate in vivo core disassembly after
host infection.
The cyclophilins represent a ubiquitous family of proteins
that are abundant in nearly every cell type and are highly
conserved through evolution (1). The main representative of
the cyclophilins in mammals is the cytosolic 18-kDa CyPA.1
The closely related CyPB (21 kDa) contains a N-terminal signal
sequence that directs this isoform to the endoplasmic reticu-
lum. A characteristic property of cyclophilins is their peptidyl-
prolyl cis-trans isomerase (PPIase) activity and their ability to
bind cyclosporin A (CsA) that inhibits the PPIase activity. In T
cells, the CsAzCyPA complex associates with and inhibits the
Ca21-dependent protein phosphatase calcineurin, resulting in
immunosuppression. Natural endogenous ligands of cyclophil-
ins with similar actions as CsA are unknown, and the cellular
functions of cyclophilins are still a matter of investigation. A
new important property of cyclophilins was found in the human
immunodeficiency virus life cycle (2, 3) when a specific associ-
ation of CyPA with the Gag polyprotein p55gag of HIV-1 (4) was
detected.
During or after budding of immature viral particles out of the
host cell, the noninfectious virions with a spherical core con-
sisting of Gag proteins are transformed to infectious virions
and undergo a dramatic structural rearrangement to an icosa-
hedral shape (5). In the course of this maturation, the pol-
encoded HIV protease processes the Gag polyprotein precursor
into three major proteins and three smaller polypeptides (6, 7).
The capsid protein p24, consisting of a N-terminal and a C-
terminal domain, condenses to form the conical core structure
surrounding the viral genome. One CyPA molecule per 10 Gag
molecules is incorporated into nascent virions, amounting to a
total of ;200 molecules/virion (2, 3). CyPB was shown to form
in vitro similar complexes with the Gag polyprotein as CyPA
but was not found in virions in vivo (2). The interaction with
the Gag polyprotein and p24 is mediated by the active site of
CyPA and is suppressed in the presence of CsA or SDZ NIM811
(3, 8), a natural nonimmunosuppressive CsA analog that also
binds to CyPA and inhibits its PPIase activity. CsA prevents
the incorporation of CyPA but inhibits neither the assembly of
viral components nor the production of morphologically intact
virions (9). However, virions lacking CyPA were found to be
considerably reduced in their propagation (10). Single point
mutations in the p24 domain of the Gag polyprotein precursor
revealed a region with an array of four proline residues to be
involved in binding to CyPA (2). Recently, the crystal structure
of CyPA complexed with a domain of p24 encompassing the
N-terminal two-thirds (residues 1–151) showed binding of
CyPA to the proline-rich segment that forms a flexible surface-
exposed loop in the mainly a-helical p24 fragment (11). The
contact region on the p24 loop is restricted to a relatively small
area with Gly-Pro90 as the central element buried in the active
site of CyPA. This Gly-Pro motif seems to be a prerequisite for
stable association. Only if glycine precedes a proline residue is
the peptide stretch able to snuggle deeply into the active site of
CyPA.
So far, the role of CyPA in the interaction with HIV-1 p24 is
not clear. CyPA might act as PPIase and catalyze a cis-trans
isomerization in the p24 peptide backbone or might function as
chaperone by binding the capsid protein in a conformation
prone for propagation, i.e. by destabilizing the capsid cone for
postentry disassembly (10). Such an action of CyPA, however,
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could not be expected to result solely from binding to the site on
the loop around Gly-Pro90 in the N-terminal domain. Very
recently, it was reported that CyPA disrupts high order p24
complexes, most probably by interfering with p24-p24 interac-
tions (12). As the assembly and disassembly of p24 occur both
in the same compartment of the host cell, it remained a puzzle
how this CyPAzp24 (Gly-Pro90) interaction should initiate cap-
sid cone disassembly without already affecting viral assembly.
In the present investigation, we have identified two addi-
tional CyPA-binding sites in the C-terminal domain of mature
p24 capsid protein. Both sites show higher affinities for CyPA
and CyPB than the Gly-Pro90 site of p24. These two high
affinity binding sites seem to be accessible for CyPA only in the
mature p24 capsid protein, i.e. after processing of immature
p24 by the HIV-1 protease. A hypothetical model of the function
of CyPA in the disassembly of the capsid cone is proposed.
EXPERIMENTAL PROCEDURES
Materials—Recombinant immature HIV-1 capsid protein was ob-
tained from D. Sizmann (Hoffmann-La Roche, Basel) in 6 M guanidine
HCl and was efficiently refolded by an established method (13, 14) into
a correctly folded soluble protein. Folded immature capsid protein was
analyzed by CD spectroscopy with regard to secondary structure com-
position. The obtained CD spectra were comparable ([u222]
mre: 215,970
millidegreeszM21zcm2) with that reported for native p24 (14). The cor-
rect mass was verified by mass spectrometry, and the protein concen-
tration was determined by quantitative amino acid analysis. The con-
centration of p24 stock solutions was always kept below 1 mg/ml to
avoid aggregation (15). PPIase-active recombinant human CyPA and
CyPB were a gift from M. Zurini (Novartis, Basel). Synthetic peptides
p(87–101), p(153–172), and p(214–228) were purchased from Neosys-
tem Laboratoire (Strasbourg).
Preparation of Mature p24—In order to obtain mature p24, folded
immature p24 protein was incubated with 1/100 (w/w) of recombinant
HIV-1 protease in 30 mM MES, pH 5.5, 200 mM NaCl, 1% (w/w) glycerol,
and 1 mM EDTA at 37 °C. The reaction was monitored by analyzing
aliquots with SDS-polyacrylamide gel electrophoresis and silver stain-
ing (Phast gels, Amersham Pharmacia Biotech). Usually, processing
was complete after 4–6 h. The reaction was stopped by adjusting the
pH to 8.0. Subsequently, 100 mM EDTA and 5 mM phenylmethanesulfo-
nyl fluoride was added, and the sample was dialyzed against 3 mM
Tris-HCl, pH 8.0, 20 mM NaCl to remove cleaved peptides (2.8 and 2.3
kDa) and vacuum-concentrated up to a concentration of #1 mg/ml. The
concentration of p24 was determined by quantitative amino acid anal-
ysis (AminoQuant, Hewlett-Packard) and was in agreement with the
concentrations determined by measuring the absorbance at 280 nm
(e280: 33.7 mM
21 cm21; Ref. 14). An aliquot (20 pmol) of the obtained
product was analyzed by liquid chromatography-mass spectrometry
(C8-reversed phase HPLC linked to an API III
1 electrospray ionization
mass spectrometer; PE-Sciex), revealing a molecular mass of 25,578.3 6
3 Da that was in agreement with the calculated molecular mass of
25,579.5 Da for mature p24. The CD spectrum of processed, i.e. mature,
p24 protein was comparable with that reported for native HIV-1 capsid
protein (14) and had a mean residue ellipticity of 213,420
millidegreeszM21zcm2 at 222 nm.
Acrylodan Labeling of p24 and Fluorescence Measurements—Folded
immature p24 (10 mM) was dialyzed against 10 mM HEPES, pH 7.0, and
10 mM dithiothreitol and then incubated with acrylodan (6-acryloyl-2-
dimethylaminonaphthalene, 10-fold molar excess over sulfhydryl
groups; Molecular Probes Europe BV) in 50 mM HEPES, pH 7.0, 5%
(v/v) acetonitrile, and 0.5 M guanidine HCl (a concentration at which
native p24 is still stable according to Ref. 14) for 2 h at room temper-
ature in the dark on a rotary device. The reaction mixture subsequently
was loaded onto a PD10 gel filtration column (Amersham Pharmacia
Biotech) and eluted with 50 mM HEPES, pH 7.0, 5% (v/v) acetonitrile,
and 0.2 M guanidine HCl. Protein (p24)-containing fractions were
pooled; dialyzed against 2 mM sodium phosphate, pH 7.4, 6 mM NaCl, 6
mM KCl, and 1% (v/v) acetonitrile; and vacuum-concentrated to a con-
centration still below 1 mg/ml. Mass and UV spectroscopy of the product
revealed only monolabeled p24 (most probably at Cys218; see Ref. 16)
with 0.3 mol of acrylodan incorporated per mol of p24. In order to obtain
acrylodan-labeled mature p24, labeled immature p24 was treated with
HIV-1 protease as described before and proven by mass spectroscopy to
be correctly processed.
Fluorescence measurements were performed at 25 °C with a spec-
trofluorimeter (model A1010 equipped with FELIX fluorescence analy-
sis software; Photon Technology International). Excitation was set to
370 nm (3-nm bandwidth), and emission was recorded from 400 to 600
nm (3-nm bandwidth). In order to measure dissociation constants of the
complexes between the cyclophilins and mature or immature p24, CyPA
or CyPB was added at the indicated concentrations to labeled mature
p24 (1.2 or 0.1 mM) or to labeled immature p24 (1.0 mM) in 20 mM sodium
phosphate, pH 7.4, 60 mM NaCl, and 60 mM KCl. After each addition,
the mixture was incubated until equilibrium had been reached before
recording the spectra. In order to calculate Kd values, the change in
relative fluorescence was fitted (SigmaPlot, Jandel Corp.) according to
the following equation: DF 5 (DFmax/2 3 Lt) 3 [(Lt 1 Pt 1 Kd) 2 {(Lt 1
Pt 1 Kd)
2 2 (4 3 Lt 3 Pt)}
0.5], where DF is the relative fluorescence
change, DFmax is the maximal change, Lt is the total concentration of
p24, Pt is the total concentration of CyP, and Kd is the dissociation
equilibrium constant. Kd values of independent experiments were
within the indicated calculated S.D. values (Table I).
PPIase Activity Measurement—PPIase activity was measured at 4 °C
essentially as recently described (17) with the standard chymotrypsin-
coupled assay (18). The assay mixture (0.08 M NaCl, 0.05 M Hepes, pH
8; final volume 200 ml) contained 50 mM of succinyl-Ala-Leu-Pro-Phe-p-
nitroanilide (Bachem) and was incubated for at least 10 min at 4 °C.
The reaction was started by the addition of chymotrypsin (60 mM) and
monitored at l 390 nm with a Hewlett-Packard 8450A UV/VIS-spectro-
photometer. For competition experiments, recombinant human CyPA
(1–5 nM) or CyPB (8–21 nM) was preincubated with or without the
corresponding p24 component in the presence of 0.5 mM bovine serum
albumin for 1 h at room temperature prior to chymotrypsin addition. In
the case of peptide p(214–228), the assay mixture additionally con-
tained 250 mM dithiothreitol. The apparent reaction rate constant kobs
was obtained by analyzing the exponential phase (50–500 s) of the
curve according to a pseudo-first order reaction. The rate of the spon-
taneous, uncatalyzed isomerization kuncat (0.0036 6 0.0002 s
21, at 4 °C)
was subtracted from kobs. The percentage inhibition was calculated in
relation to the PPIase activity measured in the absence of competitors.
In general, each measurement was performed twice, and the average
was calculated. Obtained data were fitted according to the equation for
competitive inhibition: percentage inhibition 5 [(100 3 It)/(It 1 IC50)],
where It is the total concentration of the competitor and IC50 corre-
sponds to [Ki 3 (1 1 (S/Km))]. Ki is the inhibition constant of the
competitor, S is the concentration of the PPIase substrate used in the
standard assay, and Km is the Michaelis-Menten constant of the sub-
strate. Since S/Km was approximately 1⁄20 for the used PPIase substrate,
the IC50 values are reflecting Ki values.
Mapping of CyPA-binding Sites on p24—Fragments of p24 were
obtained by incubating recombinant HIV-1 p24 protein with 1/50 (w/w)
of 1-chloro-3-tosylamido-7-amino-2-heptanone-pretreated a-chymotryp-
sin (Boehringer Mannheim) in 100 mM Tris-HCl, pH 8.0, 10 mM CaCl2
and 1 M guanidine HCl for 1 h at 37 °C. The reaction was stopped by the
addition of phenylmethanesulfonyl fluoride. An aliquot of the digested
mixture corresponding to 0.57 nmol (17.4 mg) of original p24 protein
was preincubated with or without 0.4 nmol (7.1 mg) of recombinant
human CyPA in binding buffer (20 mM Tris-HCl, pH 7.5, 60 mM NaCl,
60 mM KCl, 2 mM CaCl2, and 2 mM MgCl2) for 1 h at room temperature.
Subsequently, the reaction mixture (100 ml) was loaded onto a gel
filtration column (G25 Superfine, Amersham Pharmacia Biotech; 10 3
85 mm) and eluted with the same buffer containing 10 mM guanidine
HCl at 2 ml/min. CyPA-containing fractions (0.5 ml) were adjusted to
pH 2 with trifluoroacetic acid and were directly injected onto a C8-
reversed phase HPLC column (4.6 3 220 mm; Brownlee). Elution was
performed with HPLC buffer A (0.1% trifluoroacetic acid) and a gradi-
ent of buffer B (80% acetonitrile, 0.1% trifluoroacetic acid) at 1 ml/min.
Alternatively, recombinant HIV-1 p24 was chemically fragmented by
cyanogen bromide in 1 M guanidine HCl and 70% (v/v) trifluoroacetic
acid for 20 h at room temperature in the dark. The mixture was
lyophilized, resuspended in 5% acetonitrile and 0.1% trifluoroacetic
acid, and desalted by reversed phase HPLC. Fractions following the
run-through were pooled, vacuum-concentrated, mixed with binding
buffer, and incubated with or without CyPA for 1 h at room temperature
prior to fast gel filtration chromatography. HPLC-purified extracted
CyPA-binding peptides were N-terminally sequenced by automated
Edman degradation.
Modification of Synthetic Peptides—Biotinylation of p(87–101) was
carried out by incubating HPLC-purified peptide (in 100 mM Hepes, pH
8.0) with a 1.5-fold molar excess of NHS-Biotin (Sigma), dissolved in
Me2SO, for 1 h at room temperature. Excess reagent was trapped by the
addition of glycine (2-fold molar excess over NHS-Biotin). The product
was purified on a C18-reversed phase HPLC column (3.9 3 150 mm;
HIV-1 Capsid Protein-Cyclophilin Interaction 5327
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Waters) and proved to be correct by mass spectrometry and quantita-
tive amino acid analysis.
For acetylation of p(153–172), acetic anhydride (3-fold molar excess,
dissolved in 20 mM acetic acid) was added dropwise to a well stirred
solution of HPLC-purified peptide in 200 mM sodium phosphate, pH 7.0,
on ice. After 30 min, the reaction was stopped by the addition of 2 M
hydroxylamine HCl in 0.5 M Tris-HCl, pH 9.6. The product was purified
on a C8-reversed phase HPLC column (4.6 3 220 mm; Brownlee) and
quantified by amino acid analysis. Fragment ion mass spectrum of the
triply charged peptide ion proved the peptide to be exclusively N-
terminally acetylated.
RESULTS
Interaction of CyPA and CyPB with p24—The presence of a
reactive cysteine residue at position 218 of p24 (see Ref. 16 and
Fig. 1B) was utilized to introduce the sulfhydryl-specific, envi-
ronmentally sensitive fluorophore acrylodan (19) into imma-
ture p24 (see “Experimental Procedures”). Although formation
of an intramolecular disulfide bond between Cys198 and Cys218
has been observed in a truncated p24 encompassing the C-
terminal domain (20), such a disulfide bond could not be shown
under physiological conditions (16) and is not expected, since
the Gag precursor folds and oligomerizes in the reducing envi-
ronment of the host cell. Acrylodan-labeled immature p24 ex-
hibited maximal fluorescence emission at 498 nm when excited
at 370 nm (Fig. 2, C and D). Upon the addition of CyPA, the
fluorescence of labeled immature p24 increased in intensity
and underwent a blue shift. A dissociation equilibrium con-
stant, Kd, of 8.2 mM (Table I) was calculated from the binding
curve (Fig. 2C). In contrast, the fluorescence intensity of la-
beled immature p24 decreased upon the addition of CyPB (Fig.
2D), and a Kd of 0.9 mM (Table I) was determined. The observed
changes in relative fluorescence of labeled immature p24 upon
the addition of CyPA or -B were abolished in the presence of
CsA, yielding the same fluorescence spectrum as that of un-
bound immature p24.
In order to determine the binding characteristics of mature
p24, folded immature p24 was correctly processed to mature
p24 by the HIV-1 protease, which is also responsible for in vivo
processing of the Gag polyprotein. The fluorescence spectra of
unliganded acrylodan-labeled mature p24 exhibited maximal
emission at 508 nm (Fig. 2, A and B). The fluorescence de-
creased in intensity upon the addition of CyPA or CyPB with-
out a perceivable shift in lmax. The Kd values for the CyPAzp24
complex and for the CyPBzp24 were calculated from their re-
spective binding curves (Fig. 2, A and B; Table I). The contri-
bution of the acrylodan label to the binding of p24 to CyP was
negligible, as judged by acrylodan-labeled b-mercaptoethanol
that did not show any change in fluorescence intensity upon
CyP addition. Again, upon the addition of CsA to the mixture
of CyP and p24, the fluorescence spectrum was the same as
that of unbound p24. Thus, CsA prevented also the interac-
tions of CyPA and CyPB with labeled mature p24, demon-
strating specific binding of labeled p24 in the active site of
the cyclophilins.
PPIase Inhibition of CyP by Immature and Mature p24—To
verify the binding properties obtained with the fluorimetric
measurements, the inhibitory effect of immature p24 on the
PPIase activity of CyPA and CyPB was determined. Immature
p24 inhibited the PPIase activity of CyPB (Ki ; 1.2 mM; Fig. 3)
more efficiently than that of CyPA (Ki ; 8.5 mM). Both Ki values
were in excellent agreement with the fluorimetrically deter-
mined Kd values.
Due to the presence of a His6 tag in immature p24 (Fig. 1),
preformed complexes between CyPA and immature p24 could
be precipitated with Ni21-agarose and quantified by densito-
metric analysis of silver-stained protein bands after SDS-poly-
acrylamide gel electrophoresis. The calculated apparent disso-
FIG. 1. Scheme of immature HIV-1 capsid protein p24 (A) and
amino acid sequence of mature p24 (B). Immature p24 protein
consists of the entire p24 capsid protein (residues 1–231, B) flanked
N-terminally by a stretch of 25 amino acids (aa) including a His6 tag
and C-terminally by 20 amino acids. Similar to the genuine Gag pre-
cursor, the N-terminal extension contained 13 specific amino acid res-
idues from the matrix protein p17, whereas the C-terminal extension
contained 12 specific residues from p2, a spacer peptide linking the C
terminus of p24 to the nucleocapsid protein p7 in the original Gag
polyprotein. The cleavage sites recognized by the HIV-1 protease are
indicated by arrows. The numbering of the amino acids (B) refers to the
mature p24 capsid protein, and the MHR is indicated by shading. The
positions of the CyPA-binding fragments I–V (Fig. 4F) within p24 are
indicated. The Gly-Pro sequence elements (boldface type) are supposed
to be the central CyPA-binding segments of the peptides.
FIG. 2. Binding of CyPA and CyPB to acrylodan-labeled ma-
ture and immature p24. Titration of acrylodan-labeled mature p24 (A
and B) as well as labeled immature p24 (C and D) with recombinant
human CyPA (A and C) or CyPB (B and D) is shown as the change in
relative fluorescence at lmax. The corresponding fluorescence emission
spectra are shown in the insets, and the emission spectra of unbound
labeled p24 are indicated by dashed lines. Experimental data were
fitted as described under “Experimental Procedures,” and the calcu-
lated Kd values are summarized in Table I.
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ciation equilibrium constant Kd9 of ;19 mM obtained from
experiments in which relative low concentrations have been
used (0.25 mM p24 and 25 nM to 2.5 mM CyPA) is, as expected
(due to a certain dissociation during the procedure), higher
(;2-fold) than the Kd and Ki values (Table I). CsA efficiently
disrupted the complex (i.e. no CyPA was co-precipitated with
immature p24 in the presence of CsA).
Mature p24 was, in contrast to immature p24, susceptible to
cleavage by chymotrypsin (used in high concentrations in the
standard PPIase activity assay; see “Experimental Proce-
dures”). Most of it was found to be degraded upon analysis by
SDS-polyacrylamide gel electrophoresis at the end of the assay.
Nevertheless, the PPIase activity of CyPA and CyPB was ef-
fectively inhibited at lower concentrations of mature p24 than
of immature p24 (Fig. 3). In the case of CyPB, nanomolar
concentrations of mature p24 already inhibited part of the
PPIase activity of CyPB, but complete inhibition was achieved
only at higher concentrations (.10 mM). Therefore, the fluori-
metrically determined Kd values seem to reflect the true bind-
ing affinities of mature p24 (Table I).
Mapping the CyPA-binding Sites on the p24 Capsid Protein—
The higher affinity of mature p24 as compared with immature
p24 with cyclophilins indicates that additional binding sites on
p24 become accessible after the precursor is processed by the
HIV-1 protease. To map potential CyPA-binding sites on HIV-1
p24, chymotryptic fragments of recombinant p24 were incu-
bated with human CyPA and subjected to a fast size exclusion
chromatography (Fig. 4). CyPA-bound peptide segments of p24
co-eluted together with CyPA in the void volume. CyPA-con-
taining fractions were analyzed by reversed-phase HPLC (Fig.
4, D–F). Five CyPA-associated p24 peptides (I–V) were found
and identified by mass spectrometry. Peptide I corresponded to
the four proline residue-containing sequence 81–117, which
encompasses the known Gly-Pro90 site (Fig. 1B). The molecular
mass of peptide II mapped to C-terminal fragment 187–227 of
mature p24 containing a Gly-Pro sequence element. Peptides
III, IV, and V, consisting of residues 152–185, 130–164, and
153–187, respectively, overlap in the major homology region
(MHR) of p24 (21), all having two proline residues and a Gly-
Pro sequence element.
To confirm the binding of the proteolytic p24 fragments to
CyPA, the same procedure was performed with cyanogen bro-
mide-fragmented p24. Two CyPA-bound peptides were sub-
jected to N-terminal amino acid sequence analysis. The ob-
tained N-terminal sequences YXPTSILDIKQ and TAXQGVG,
where X denotes an unidentified amino acid residue, corre-
sponded to cyanogen bromide-generated fragments 145–185
and 216–235, respectively (Fig. 1). Both peptides thus matched
the two new binding sites on p24 found with the chymotryptic
fragments.
PPIase Inhibition of CyP by p24 Peptide Segments—Syn-
thetic peptides, corresponding to the chymotryptic fragments
with Gly-Pro as the central binding motif, were used to confirm
and to define the new CyP-binding sites on p24. The binding
properties of these p24 peptides were examined by means of
their inhibitory effect on the PPIase activity of CyPA and
CyPB. Peptide p(87–101), corresponding to a segment within
peptide I, inhibited the PPIase activity of CyPA with a Ki of 170
TABLE I
Inhibition (Ki) and dissociation equilibrium (Kd) constants of various ligands for cyclophilins
Ligands







Immature p24c 8.5 (0.3) 8.2 (1.0) 1.2 (0.1) 0.90 (0.22)
Mature p24 Inh.d 0.6 (0.1) Inh.d 0.25 (0.06)
Peptide p (87–101) HAGPIAPGQMREPRG 170 (48) NDf
Peptide p (87–101)e biotin-HAGPIAPGQMREPRG 28 (2) ND
Peptide I (81–117)g DRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGW 8.3 (0.8) 8.4 (0.9)
Peptide p (153–172)h Ac-IRQGPKEPFRDYVDRFYKTL Inh.d #1i Inh.d #1i
Peptide p (214–228)j MMTACQGVGGPGHKA 0.35 (0.07) 0.40 (0.02)k 0.29 (0.06) 0.29 (0.02)k
a Ki values were obtained by inhibiting PPIase activity as described in Fig. 3. In parentheses, the calculated S.D. values obtained from the curve
fittings are shown.
b Kd values were obtained as described in Fig. 2.
c See Fig. 1.
d Inh., inhibition was observed already at low concentrations, but a true Ki value could not be determined (see text).
e N-terminally biotinylated peptide.
f ND, not determined.
g Peptide representing the entire loop around Gly-Pro90 of p24 (Fig. 1B).
h N-terminally acetylated peptide belonging to the MHR of p24.
i Estimated value (see text).
j Peptide from the C terminus of p24.
k Acrylodan-labeled peptide.
FIG. 3. Inhibition of the PPIase ac-
tivity of CyPA and CyPB each by im-
mature (circles) or mature (squares)
p24. PPIase activity was measured and
calculated as described under “Experi-
mental Procedures.” The Ki values of im-
mature p24 are summarized in Table I.
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mM (Table I). The elimination of the positive charge by biotiny-
lation of the N terminus improved the binding 6-fold (Table I),
whereas biotin itself did not affect the PPIase activity in con-
centrations of up to 0.2 mM. Additional amino acid residues
preceding His87 contributed to better binding of peptide I (Ki of
8.3 mM), which encompasses the entire sequence of the surface-
exposed loop between helices 4 and 5 of p24 (Fig. 5A; Table I).
Peptide I was purified from the chymotrypsin digest of p24 in
amounts sufficient for the inhibition studies.
The N-acetylated synthetic MHR peptide p(153–172) was
shown to inhibit the PPIase activity of CyPA and CyPB already
at lower concentrations (Fig. 5B) compared with peptide I (Fig.
5A). The experimental data displayed a complex inhibition
behavior due to the fragmentation of the Phe-containing MHR
peptide during the time of activity measurement by chymotryp-
sin, which was present in high concentrations in the standard
PPIase assay. Apparently, the inhibition curves reflect a het-
erogeneous and dynamic inhibition of the PPIase activities by a
mixture of truncated MHR peptides, whose individual affinities
will be lower than that of the original MHR peptide. Thus, only
IC50 values of 12 and 27 mM for CyPA and CyPB, respectively,
could be determined. The effective concentrations of intact
MHR peptide must be much lower than the indicated concen-
trations (Fig. 5B). The observed partial inhibition at initial
concentrations of the peptide below 0.1 mM, however, shows
that intact MHR peptides are able to bind to the active site of
both cyclophilins at very low concentrations. This suggests the
MHR peptide to be a high affinity ligand for CyPA (Kd # 1 mM)
if residues following Phe161 are not cleaved off by chymotryp-
sin. The fact that complexes of CyPA with chymotryptic or
cyanogen bromide fragments of p24 encompassing the MHR
could be isolated (Fig. 4F) corroborates this conclusion.
Peptide p(214–228), corresponding to the C-terminal binding
site on p24, displayed a homogeneous competitive inhibition of
PPIase activity and seems to have the highest affinity toward
CyPA (Ki of 0.35 mM) and CyPB (Ki of 0.29 mM) among the three
identified p24 binding sites (Fig. 5C; Table I). The presence of
a cysteine residue (Cys218) allowed us to label this peptide with
acrylodan (for details, see Ref. 22) and to measure its interac-
tions with CyPA and CyPB. The calculated Kd values 0.40 and
0.29 mM, respectively, corresponded excellently with the Ki
values determined by the competitive PPIase assay (Table I),
emphasizing the equivalence of the different methods applied.
DISCUSSION
The results presented in this study indicate that HIV-1 cap-
sid protein p24 contains, in total, three sites that are able to
interact specifically with CyPA and CyPB. One binding site,
the low affinity site, matches to the loop around Gly-Pro90,
which has been previously proposed on the basis of mutation
experiments (2) and verified by crystallographic analysis of the
complex of CyPA with CA151, a truncated p24 encompassing
the N-terminal domain (11). The reported Kd of ;16 mM for the
CA151zCypA complex (23) is comparable with the present value
of 8 mM for peptide I (Table I). The two additional binding sites,
one within the MHR and another at the very C terminus of
mature p24, show higher affinities and were not known so far.
Both of them contain the Gly-Pro motif, which was shown to be
the central element and a prerequisite for binding to CyPA (11,
24). A homology among the Gly-Pro adjacent amino acid resi-
dues of the three binding sites is not evident. The more than
20-fold higher affinity of CyPA for the C-terminal peptide than
for the Gly-Pro90 peptides might be attributed to the presence
of an additional Gly and of positive charged amino acid resi-
dues in the segment following Gly-Pro224 (Table I). A homolo-
gous peptide containing the sequence SIHIGPGRAF and which
fulfills the above criteria was shown to bind to CyPA with a Kd
FIG. 4. Extraction of CyPA-bound p24 peptide fragments by
differential gel filtration chromatography. CyPA (A), chymotryp-
sin-digested p24 (B), and a preincubated mixture (C) of the same
amounts of CyPA and chymotrypsin-digested p24 were subjected to a
fast gel filtration chromatography, according to “Experimental Proce-
dures.” Panels D–F show the corresponding HPLC chromatograms of
fraction 5 of the preceding gel filtration. HPLC fractions containing
CyPA-bound p24 fragments (F) were subjected to mass spectrometry.
The p24 fragments had the following molecular masses: 3980.67 6 0.65
(I), 4208.60 6 0.52 (II), 4188.97 6 0.20 (III), 4239.72 6 0.22 (IV), and
4303.72 6 0.35 (V).
FIG. 5. Inhibition of PPIase activity
by p24 peptides corresponding to the
deduced CyPA-binding sites. Either
CyPA (filled circles) or CyPB (hollow cir-
cles) was preincubated with the indicated
concentrations of peptide I (A) represent-
ing the entire surface-exposed loop be-
tween helices 4 and 5 of p24 (Figs. 1B and
4F), N-acetylated peptide p(153–172) (B)
representing the major homology region,
or peptide p(214–228) (C) from the C
terminus of p24. PPIase activity was
measured and calculated as described
under “Experimental Procedures.” The
determined Ki values are summarized in
Table I.
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of 0.33 mM and to CyPB with a Kd of 0.19 mM (22). Basic
residues, C-terminal of Gly-Pro, are also found in the MHR
peptide p(153–172), which binds more tightly to the cyclophil-
ins than the Gly-Pro90 peptides if the residues following Phe161
are still present (see “Results”). The crystallographic studies of
the low affinity binding site revealed that the Gly-Pro90 adja-
cent residues predominantly interact with CyPA by their back-
bone atoms (11, 25). The present results with the two high
affinity binding sites, however, demonstrate significant contri-
butions of GP-flanking side chains to the binding to cyclophilins.
Whereas complex formation of CyPA and CyPB with the p24
peptides was comparable, substantial differences in affinity
were found with mature and immature p24. The immature
protein form has, like the unprocessed Gag polyprotein precur-
sor, an N- and C-terminal extension (Fig. 1) that seems to be
important for proper assembly of the initial virion core shell
(26–29) and thus probably also for its proper conformation. The
binding affinity of CyPA for immature p24 (Kd ; 8.3 mM) is
identical with that for the Gly-Pro90 site. These results suggest
that the binding of CyPA to immature p24 occurs through the
Gly-Pro90 site, as proposed previously (2, 11, 23, 30). In con-
trast to CyPA, the affinity of CyPB for immature p24 is 8-fold
higher (Kd ;1 mM) indicating a complex formation via a differ-
ent binding site on p24, most likely the MHR. Evidence for a
different binding site for CyPB on immature (i.e. unprocessed)
p24, compared with CyPA, is given by the different fluores-
cence changes upon the addition of the cyclophilins (Fig. 2, C
and D) but also by the observation that two Gag mutants,
which had either Gly89 or Pro90 exchanged for Ala, lost their
ability to bind CyPA but were still able to associate with CyPB
(2, 9). The stronger interaction of the Gag polyprotein with
CyPB than with CyPA explains why 10-fold higher concentra-
tions of CsA are needed to disrupt this complex (4).
Processing the immature p24 protein to the mature p24 form
of the capsid protein by HIV-1 protease increased the affinity
13- and 4-fold for CyPA and CyPB, respectively. The agreement
of the Kd values for mature p24 with that for peptide p(214–
228) suggests the C-terminal binding site to be responsible for
the high affinity interaction of the mature p24 form with the
cyclophilins and not the Gly-Pro90 site. The fluorescence inten-
sity of acrylodan-labeled immature p24 increased upon CyPA
binding, resulting in a Kd of 8.2 mM, whereas that of labeled
mature p24, carrying the environmentally sensitive label at the
same site, decreased upon the addition of already low concen-
trations of CyPA. This observation indicates different primary
interaction sites of immature and mature p24 with CyPA and
thus different conformations of the two p24 forms. The induced
accessibility of the C-terminal binding site(s) on maturation
has to be caused by a conformational rearrangement in the
C-terminal domain of the capsid protein or by the loss of N-
terminal and C-terminal extensions of immature p24. The ob-
served processing-induced change in the fluorescence spectrum
of unliganded p24 (Fig. 2, A and B versus C and D) indicates a
structural rearrangement, particularly in the C-terminal do-
main where the label is attached (see “Experimental Proce-
dures”). A maturation-induced accessibility of the MHR-located
binding site for CyPA is also indicated by the comparable
estimated Kd for the MHR peptide p(153–172) (see discussion
under “Results”) and for the mature p24 protein. The recently
reported structure of the C-terminal domain of p24 (20) sug-
gests that both high affinity binding sites are accessible for
CyPA. Structural data of the C-terminal 11 amino acids, in-
cluding Gly223-Pro224, however, could not be collected, suggesting
a rather flexible structure. Thus, this part of p24 is very likely
to be as well suited as the free peptide to fit into the active site
of CyPA and CyPB as predicted from the present study.
That the high affinity interaction of CypA with p24 was not
detected in previous isothermal titration experiments with di-
rectly expressed mature recombinant p24 (23) might well be
due to the different experimental conditions. The fluorescence
method applied in the present study allowed measurements at
50–500-fold lower concentrations of p24, thus avoiding aggre-
gations of p24 that occur at higher concentrations (15) and that
could have disturbed the accessibility of the high affinity sites
in isothermal titration experiments. Differences in conforma-
tions due to different manufacturing methods of the mature
p24 might be another reason. In the present study, mature p24
was prepared, similar as in vivo, from a folded precursor that
was processed as in vivo by the HIV-1 protease.
Role of CyPA-p24 Interaction—Growing evidence empha-
sizes the role of different cyclophilin-binding sites on a single
p24 molecule. During viral assembly of the Gag polyprotein
precursors, the essential incorporation of CyPA into the virion
is mediated by its binding to the Gly-Pro90 site, which, at this
stage, is according to the present results the only accessible
CyPA binding site. The ratio of only one incorporated CyPA to
10 Gag polyproteins (2, 3) might reflect the moderate binding
affinity, as has been already discussed (23). A function of viri-
on-incorporated CyPA in the viral assembly process has been
ruled out (9); rather, a role in capsid cone disassembly after
viral infection, possibly by weakening the capsid cone already
prior to viral host penetration, has been postulated (10). The
present results suggest that virus-incorporated CyPA bound to
the Gly-Pro90 site might be attracted in the course of the
maturation process by the newly generated higher affinity
binding sites in the C-terminal domain of p24, which is impor-
tant for p24 oligomerization (Fig. 6). Indeed, CyPA disrupts
high order p24 complexes (12) but obviously allows assembly of
the C-terminal domain-missing capsid protein (CA151) into con-
tinuous planar strips even if it is bound to the Gly-Pro90 site
(11). The function of C-terminal domain-bound CyPA could
thus be to promote destabilization of the capsid cone structure.
This hypothesis would be in agreement with the observation
that propagation of virions generated in the presence of CsA,
which abolishes CyPA incorporation, is blocked after infection
(9). Obviously, the absence of CyPA in the virus cannot be
compensated by abundant cytosolic CyPA after infection of a
target cell (3, 9). If the Gly-Pro90 site would indeed remain the
target of CyPA action, cytosolic CyPA should be able to substi-
tute CyPA deficiency after viral entry, due to the outside expo-
sure and accessibility of this loop on the capsid cone. In con-
trast, the C-terminal binding sites in the mature capsid cone
FIG. 6. Model of CyPA action on the capsid cone architecture.
The capsid protein p24 of HIV-1 is supposed to dimerize by interactions
between the N-terminal domains (N) of two p24 molecules and to
oligomerize to higher order structures by aggregation of p24 dimers
through their C-terminal domains (C) containing the MHR (20, 34).
After processing of the Gag polyprotein and due to conformational
changes, high affinity binding sites for cyclophilins are generated in the
C-terminal domain of p24 additionally to the low affinity Gly-Pro90 site
in the N-terminal domain. Cyclophilin interaction in the C-terminal
domain is expected to destabilize the capsid cone for postinfection
disassembly.
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might be accessible to cellular cyclophilins after infection only,
if the regularity and stability of the structure of the capsid cone
is impaired, by virus-intrinsic CyPA molecules. In some cases,
destabilizing mutations in p24 (31, 32) might dispense the
virus from incorporation of CyPA. Intracellular cyclophilins
and possibly other components might then facilitate complete
disassembly. If the capsid cone is not destabilized, initiation of
the disassembly process will be difficult but might be possible
in cells with high concentrations of intracellular cyclophilins,
as was recently observed (33).
In conclusion, the present finding of two high affinity binding
sites for CyPA and CyPB within the C-terminal domain of
HIV-1 p24 revealed not only sequence motifs of Gly-Pro flank-
ing regions that are important for tight binding of peptide
ligands to the cyclophilins but also a feasible model for the
cyclophilin-capsid protein interactions in the HIV-1 life cycle
(Fig. 6). CyPA is incorporated into the virions by binding to the
Gly-Pro90 site (N-terminal domain of p24) of the Gag polypro-
tein precursor. Processing of Gag proteins by the viral protease
induces a conformational change and generates high affinity
binding sites in the C-terminal domain of p24 that will attract
CyPA, and this complex could destabilize the capsid cone for
disassembly. In view of the observed binding of CyPA to a site
in the MHR of p24, which is well conserved in HIV-1, HIV-2,
and other lentiviruses as well as in oncoviruses, intracellular
cyclophilins might well be the postulated highly conserved
binding partner for this region (20).
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